Imaging EGFR and HER3 through 89Zr-labeled MEHD7945A (Duligotuzumab). Academic Article uri icon

Overview

abstract

  • Tumor resistance to treatment paved the way toward the development of single agent drugs that target multiple molecular signatures amplified within the malignancy. The discovered crosstalk between EGFR and HER3 as well as the role of HER3 in mediating EGFR resistance made these two receptor tyrosine kinases attractive targets. MEHD7945A or duligotuzumab is a single immunotherapy agent that dually targets both molecular signatures. In this study, a positron emission tomography (PET) companion diagnostic to MEHD7945A is reported and evaluated in pancreatic cancer. Tumor accretion and whole body pharmacokinetics of 89Zr-MEHD7945A were established. Specificity of the probe for EGFR and/or HER3 was further examined.

publication date

  • June 13, 2018

Research

keywords

  • Immunoglobulin G
  • Pancreatic Neoplasms
  • Positron-Emission Tomography
  • Receptor, ErbB-3

Identity

PubMed Central ID

  • PMC5998059

Scopus Document Identifier

  • 85048474708

Digital Object Identifier (DOI)

  • 10.1042/BCJ20160690

PubMed ID

  • 29899472

Additional Document Info

volume

  • 8

issue

  • 1